Impact of body dose parameters on circulating immune cells in locally advanced nasopharyngeal carcinoma patients: a retrospective cohort study

Jianyun JIANG; Ruiping ZHAI; Hongmei YING

doi:10.19401/j.cnki.1007-3639.2023.10.002

您当前的位置：

首页 >

文章列表页 >

Impact of body dose parameters on circulating immune cells in locally advanced nasopharyngeal carcinoma patients: a retrospective cohort study

Article | 更新时间：2025-12-31

- Impact of body dose parameters on circulating immune cells in locally advanced nasopharyngeal carcinoma patients: a retrospective cohort study
- China Oncology Vol. 33, Issue 10, Pages: 898-907(2023)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院放射治疗中心，复旦大学上海医学院肿瘤学系，上海 200032
  2. 上海市放射肿瘤学重点实验室，上海 200032
  3. 上海市放射治疗临床医学研究中心，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.10.002
  CLC： R739.62；R739.63
- Received：12 June 2023，
  
  Revised：2023-09-19，
  
  Published：30 October 2023
- 稿件说明：
移动端阅览
Jianyun JIANG, Ruiping ZHAI, Hongmei YING. Impact of body dose parameters on circulating immune cells in locally advanced nasopharyngeal carcinoma patients: a retrospective cohort study[J]. China Oncology, 2023, 33(10): 898-907.
DOI：

Jianyun JIANG, Ruiping ZHAI, Hongmei YING. Impact of body dose parameters on circulating immune cells in locally advanced nasopharyngeal carcinoma patients: a retrospective cohort study[J]. China Oncology, 2023, 33(10): 898-907. DOI： 10.19401/j.cnki.1007-3639.2023.10.002.

摘要

背景与目的：

调强适形放疗（intensity-modulated radiotherapy，IMRT）可显著提升局部晚期鼻咽癌患者的生存结局，然而该疗法仍未能满足局部晚期鼻咽癌（locally-advanced nasopharyngeal carcinoma，LANPC）患者的预后需求，因此，确定有效的预后预测标志物对于改善放疗的效果和实现个体化治疗至关重要。由于放疗相关的身体剂量参数和免疫炎性标志物在以往的研究中显示出潜在的预测价值，本研究旨在探讨局部晚期鼻咽癌患者放疗过程中身体剂量参数与免疫细胞减少及预后之间的关系。

方法：

回顾性分析了2012年1月1日—2016年12月31日在复旦大学附属肿瘤医院接受根治性放疗的423例LANPC患者（Ⅲ ~ Ⅳa期）的临床资料，研究IMRT期间多种免疫细胞的百分比变化范围。采用Cox比例风险回归模型来确定患者总生存（overall survival，OS）、局部无复发生存（locoregional relapse-free survival，LRFS）和无远处转移生存（distant metastasis-free survival，DMFS）的独立预后因素。从剂量-体积直方图（dose-volume diagrams，DVH）中获取一系列身体剂量参数（body dose parameters），采用logistic回归确定与白细胞变化相关的影响因素。

结果：

较高的淋巴细胞变化范围[ΔLYM%≥77.0%（high ΔLYM%）

]

和较高的单核细胞变化范围[ΔMONO%≥28.5%（high ΔMONO%）

]

是局部晚期鼻咽癌患者的两个不良预后因素。多因素分析结果显示，high ΔLYM%被证明是OS（HR = 1.672，

= 0.012）、LRFS（HR = 1.712，

= 0.006）和DMFS（HR = 1.971，

= 0.001）的不良预后因素；High ΔMONO%可作为OS（HR = 1.355，

= 0.015）和DMFS（HR = 1.704，

= 0.003）的不良预后因素。ΔLYM%变化值受身体剂量参数中的身体辐照总剂量（integral body dose，IBD）（OR = 1.004，

= 0.037）和body V

（OR = 1.046，

= 0.036）的影响，而ΔMONO%受body V

（OR = 1.144，

= 0.009）和V

（OR = 0.734，

= 0.022）的影响。

结论：

IBD、body V

和body V

、V

可作为放疗计划中的剂量限制区域，以减轻对淋巴细胞和单核细胞的消耗，进一步改善预后。

Abstract

Background and purpose:

The implementation of intensity-modulated radiotherapy (IMRT) has significantly enhanced the survival outcomes for patients with nasopharyngeal carcinoma (NPC). However

this therapeutic approach still falls short in meeting the prognostic requirements of individuals with locally advanced NPC (LANPC). Therefore

it is imperative

to identify effective prognostic markers to enhance the efficacy of radiotherapy and achieve personalized treatment. Given the potential predictive value demonstrated in previous studies regarding radiotherapy-related body dose parameters and immune blood cells

this study aimed to investigate the correlation between body dose parameters and reduced immune cells and patient prognosis during radiotherapy in LANPC patients.

Methods:

Clinical data of 423 patients with LANPC (stage Ⅲ-Ⅳa) treated in Fudan University Shanghai Cancer Center from Jan.1

2012 to Dec. 31

2016 were retrospectively analyzed. Percentage changes of different immune blood cells during radiotherapy were also collected. Cox proportional hazard model was used to determine prognostic factors for overall survival (OS)

locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS). Body dose-based parameters were extracted from dose-volume histograms (DVHs). Logistic regression was applied to determine parameters that could predict white blood cells reduction.

Results:

High ΔLYM% (ΔLYM%≥7 7.0%) and high ΔMONO% (ΔMONO%≥2 8.5%) were identified as two adverse prognostic factors in LANPC patients. In multivariable analysis

high ΔLYM% was found to be a significant predictor of worse OS (HR = 1.672

= 0.012)

LRFS (HR = 1.712

= 0.006)

and DMFS (HR = 1.971

= 0.001). High ΔMONO% was associated with worse OS (HR = 1.355

= 0.015) and DMFS (HR = 1.704

= 0.003). The change of ΔLYM% was influenced by the integral body dose (IBD) (OR = 1.004

= 0.037) and body V

(OR = 1.046

= 0.036). ΔMONO% was significantly affected by body V

(OR = 1.144

= 0.009) and V

(OR = 0.734

= 0.022).

Conclusion:

Integral body dose

and V

can serve as dose-volume co

nstraints to retain sufficient immune cell populations to improve prognosis.

关键词

Keywords

references

LEE A W M , MA B B Y , NG W T , et al. Management of nasopharyngeal carcinoma: current practice and future perspective [J ] . J Clin Oncol , 2015 , 33 ( 29 ): 3356 - 3364 . DOI: 10.1200/JCO.2015.60.9347 http://doi.org/10.1200/JCO.2015.60.9347

BLANCHARD P , LEE A , MARGUET S , et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis [J ] . Lancet Oncol , 2015 , 16 ( 6 ): 645 - 655 . DOI: 10.1016/S1470-2045(15)70126-9 http://doi.org/10.1016/S1470-2045(15)70126-9

ZHANG M X , LI J , SHEN G P , et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up [J ] . Eur J Cancer , 2015 , 51 ( 17 ): 2587 - 2595 . DOI: 10.1016/j.ejca.2015.08.006 http://doi.org/10.1016/j.ejca.2015.08.006 https://linkinghub.elsevier.com/retrieve/pii/S0959804915007819 https://linkinghub.elsevier.com/retrieve/pii/S0959804915007819

SUN X M , SU S F , CHEN C Y , et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities [J ] . Radiother Oncol , 2014 , 110 ( 3 ): 398 - 403 . DOI: 10.1016/j.radonc.2013.10.020 http://doi.org/10.1016/j.radonc.2013.10.020

COLEVAS A D , YOM S S , PFISTER D G , et al. NCCN guidelines insights: head and neck cancers, version 1.2018 [J ] . J Natl Compr Canc Netw , 2018 , 16 ( 5 ): 479 - 490 . DOI: 10.6004/jnccn.2018.0026 http://doi.org/10.6004/jnccn.2018.0026 https://jnccn.org/doi/10.6004/jnccn.2018.0026 https://jnccn.org/doi/10.6004/jnccn.2018.0026

SUN W , ZHANG L L , LUO M , et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio [J ] . Head Neck , 2016 , 38 ( Suppl 1 ): E1332 -E1340.

JIN T , LIU N F , JIN Q F , et al. Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study [J ] . Radiat Oncol , 2022 , 17 ( 1 ): 176 . DOI: 10.1186/s13014-022-02147-7 http://doi.org/10.1186/s13014-022-02147-7

CORBEAU A , KUIPERS S C , DE BOER S M , et al. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review [J ] . Radiother Oncol , 2021 , 164 : 128 - 137 . DOI: 10.1016/j.radonc.2021.09.009 http://doi.org/10.1016/j.radonc.2021.09.009

ZHAI R P , KONG F F , DU C R , et al. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: clinical and dosimetric predictors in a prospective cohort study [J ] . Oral Oncol , 2017 , 68 : 44 - 49 . DOI: 10.1016/j.oraloncology.2017.03.005 http://doi.org/10.1016/j.oraloncology.2017.03.005 https://linkinghub.elsevier.com/retrieve/pii/S1368837517300593 https://linkinghub.elsevier.com/retrieve/pii/S1368837517300593

TERRONES-CAMPOS C , LEDERGERBER B , VOGELIUS I R , et al. Hematological toxicity in patients with solid malignant tumors treated with radiation-temporal analysis, dose response and impact on survival [J ] . Radiother Oncol , 2021 , 158 : 175 - 183 . DOI: 10.1016/j.radonc.2021.02.029 http://doi.org/10.1016/j.radonc.2021.02.029 https://linkinghub.elsevier.com/retrieve/pii/S0167814021060928 https://linkinghub.elsevier.com/retrieve/pii/S0167814021060928

LIU L T , LIANG Y J , GUO S S , et al. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA [J ] . Head Neck , 2022 , 44 ( 1 ): 34 - 45 . DOI: 10.1002/hed.v44.1 http://doi.org/10.1002/hed.v44.1 https://onlinelibrary.wiley.com/toc/10970347/44/1 https://onlinelibrary.wiley.com/toc/10970347/44/1

TANG C , LIAO Z X , GOMEZ D , et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes [J ] . Int J Radiat Oncol Biol Phys , 2014 , 89 ( 5 ): 1084 - 1091 . DOI: 10.1016/j.ijrobp.2014.04.025 http://doi.org/10.1016/j.ijrobp.2014.04.025 https://linkinghub.elsevier.com/retrieve/pii/S0360301614004969 https://linkinghub.elsevier.com/retrieve/pii/S0360301614004969

JOSEPH N , MCWILLIAM A , KENNEDY J , et al. Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy [J ] . Radiother Oncol , 2019 , 135 : 115 - 119 . DOI: S0167-8140(19)30112-4 http://doi.org/S0167-8140(19)30112-4

DAVULURI R , JIANG W , FANG P , et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy [J ] . Int J Radiat Oncol Biol Phys , 2017 , 99 ( 1 ): 128 - 135 . DOI: 10.1016/j.ijrobp.2017.05.037 http://doi.org/10.1016/j.ijrobp.2017.05.037 https://linkinghub.elsevier.com/retrieve/pii/S0360301617309756 https://linkinghub.elsevier.com/retrieve/pii/S0360301617309756

WEEKE E . The development of lymphopenia in uremic patients undergoing extracorporeal irradiation of the blood with portable beta units [J ] . Radiat Res , 1973 , 56 ( 3 ): 554 - 559 .

XIE X X , GONG S L , JIN H K , et al. Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count [J ] . Radiat Oncol , 2020 , 15 ( 1 ): 65 . DOI: 10.1186/s13014-020-01494-7 http://doi.org/10.1186/s13014-020-01494-7

HIRATA F , ISHIYAMA K , TANAKA Y , et al. Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis [J ] . Ann Gastroenterol Surg , 2018 , 2 ( 5 ): 383 - 393 . DOI: 10.1002/ags3.12195 http://doi.org/10.1002/ags3.12195

XIANG X Y , DING Z , ZENG Q , et al. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy [J ] . Radiat Oncol , 2022 , 17 ( 1 ): 48 . DOI: 10.1186/s13014-022-02018-1 http://doi.org/10.1186/s13014-022-02018-1

CHUA M L , TAN S H , KUSUMAWIDJAJA G , et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials [J ] . Eur J Cancer , 2016 , 67 : 119 - 129 . DOI: 10.1016/j.ejca.2016.08.006 http://doi.org/10.1016/j.ejca.2016.08.006 https://linkinghub.elsevier.com/retrieve/pii/S095980491632367X https://linkinghub.elsevier.com/retrieve/pii/S095980491632367X

LI X H , CHANG H , XU B Q , et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study [J ] . Cancer Med , 2017 , 6 ( 1 ): 310 - 319 . DOI: 10.1002/cam4.2017.6.issue-1 http://doi.org/10.1002/cam4.2017.6.issue-1 https://onlinelibrary.wiley.com/toc/20457634/6/1 https://onlinelibrary.wiley.com/toc/20457634/6/1

CHO O , OH Y T , CHUN M , et al. Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer [J ] . Head Neck , 2016 , 38 ( Suppl 1 ): E1061 -E1067.

LIU L T , CHEN Q Y , TANG L Q , et al. The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients [J ] . Cancer Res Treat , 2018 , 50 ( 1 ): 19 - 29 . DOI: 10.4143/crt.2016.595 http://doi.org/10.4143/crt.2016.595 http://www.e-crt.org/journal/view.php?doi=10.4143/crt.2016.595 http://www.e-crt.org/journal/view.php?doi=10.4143/crt.2016.595

VENKATESULU B P , MALLICK S , LIN S H , et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors [J ] . Crit Rev Oncol Hematol , 2018 , 123 : 42 - 51 . DOI: S1040-8428(17)30349-9 http://doi.org/S1040-8428(17)30349-9

DU C R , NI M S , JIANG J Y , et al. Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis [J ] . Eur Arch Otorhinolaryngol , 2022 , 279 ( 8 ): 3947 - 3956 . DOI: 10.1007/s00405-021-07192-8 http://doi.org/10.1007/s00405-021-07192-8

LEE Y J , AUH S L , WANG Y G , et al. Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: changing strategies for cancer treatment [J ] . Blood , 2009 , 114 ( 3 ): 589 - 595 .

SO T H , LAM K O . The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy: Asian perspectives in the immunotherapy era [J ] . Radiother Oncol , 2020 , 147 : 144 . DOI: 10.1016/j.radonc.2020.05.025 http://doi.org/10.1016/j.radonc.2020.05.025 https://linkinghub.elsevier.com/retrieve/pii/S0167814020302814 https://linkinghub.elsevier.com/retrieve/pii/S0167814020302814

RYBKINA V L , AZIZOVA T V , SCHERTHAN H , et al. Expression of blood serum proteins and lymphocyte differentiation clusters after chronic occupational exposure to ionizing radiation [J ] . Radiat Environ Biophys , 2014 , 53 ( 4 ): 659 - 670 . DOI: 10.1007/s00411-014-0556-3 http://doi.org/10.1007/s00411-014-0556-3

BALÁZS K , KIS E , BADIE C , et al. Radiotherapy-induced changes in the systemic immune and inflammation parameters of head and neck cancer patients [J ] . Cancers (Basel) , 2019 , 11 ( 9 ): 1324 . DOI: 10.3390/cancers11091324 http://doi.org/10.3390/cancers11091324 https://www.mdpi.com/2072-6694/11/9/1324 https://www.mdpi.com/2072-6694/11/9/1324

LUO-OWEN X , PECAUT M J , RIZVI A , et al. Low-dose total-body γ irradiation modulates immune response to acute proton radiation [J ] . Radiat Res , 2012 , 177 ( 3 ): 251 - 264 . DOI: 10.1667/RR2785.1 http://doi.org/10.1667/RR2785.1 http://www.bioone.org/doi/10.1667/RR2785.1 http://www.bioone.org/doi/10.1667/RR2785.1

WANG L J , GUO Y S , XU J H , et al. Clinical analysis of recurrence patterns in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy [J ] . Ann Otol Rhinol Laryngol , 2017 , 126 ( 12 ): 789 - 797 . DOI: 10.1177/0003489417734229 http://doi.org/10.1177/0003489417734229 http://journals.sagepub.com/doi/10.1177/0003489417734229 http://journals.sagepub.com/doi/10.1177/0003489417734229

SANFORD N N , LAU J , LAM M B , et al. Individualization of clinical target volume delineation based on stepwise spread of nasopharyngeal carcinoma: Outcome of more than a decade of clinical experience [J ] . Int J Radiat Oncol Biol Phys , 2019 , 103 ( 3 ): 654 - 668 . DOI: 10.1016/j.ijrobp.2018.10.006 http://doi.org/10.1016/j.ijrobp.2018.10.006 https://linkinghub.elsevier.com/retrieve/pii/S0360301618338574 https://linkinghub.elsevier.com/retrieve/pii/S0360301618338574

BYUN H K , KIM N , YOON H I , et al. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era [J ] . Radiat Oncol , 2019 , 14 ( 1 ): 51 . DOI: 10.1186/s13014-019-1256-6 http://doi.org/10.1186/s13014-019-1256-6

WANG X , ZHAO Z X , WANG P L , et al. Low lymphocyte count is associated with radiotherapy parameters and affects the outcomes of esophageal squamous cell carcinoma patients [J ] . Front Oncol , 2020 , 10 : 997 . DOI: 10.3389/fonc.2020.00997 http://doi.org/10.3389/fonc.2020.00997

JIN J Y , HU C , XIAO Y , et al. Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage Ⅲ NSCLC: a secondary analysis of RTOG0617 [J ] . Cancers (Basel) , 2021 , 13 ( 24 ): 6193 . DOI: 10.3390/cancers13246193 http://doi.org/10.3390/cancers13246193 https://www.mdpi.com/2072-6694/13/24/6193 https://www.mdpi.com/2072-6694/13/24/6193

VENKATESULU B , GIRIDHAR P , PUJARI L , et al. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): a systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy [J ] . Radiother Oncol , 2022 , 177 : 81 - 94 . DOI: 10.1016/j.radonc.2022.10.019 http://doi.org/10.1016/j.radonc.2022.10.019

WANG Y F , DENG W Y , LI N , et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions [J ] . Front Pharmacol , 2018 , 9 : 185 . DOI: 10.3389/fphar.2018.00185 http://doi.org/10.3389/fphar.2018.00185

Views

2140

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Impact of radiation-induced lymphopenia on prognosis in patients with limited-stage small cell lung cancer: a cohort study

Value of pretreatment ¹⁸F-FLT PET/CT and ¹⁸F-FDG PET/CT uptake heterogeneity for early prediction of treatment outcome in locally advanced nasopharyngeal carcinoma

The effect of paclitaxel on the peripheral blood lymphocytes in early stage breast cancer

Related Author

Yihua WANG

Yaqi LI

Yulei PEI

Kailiang WU

Xingwen FAN

Guang MA

Xiaomin OU

Chaosu HU

Related Institution

Department of Thoracic Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Oncology, Taiyuan Central Hospital/The Ninth Clinical Medical College of Shanxi Medical University

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Center for Biomedical Imaging, Fudan University; Shanghai Engineering Research Center for Molecular Imaging Probes

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

中山市人民医院乳腺外科

AI问答

⁰